CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD

CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone

Published:2022-07 Issue:6 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Bose Sminu¹^ORCID,Lee Tristan²^ORCID,Choi Shaelyn¹,Fazlollahi Ladan³,Rasiej Michael J.⁴^ORCID,Schwartz Gary K.¹,Ingham Matthew¹^ORCID

Affiliation:

1. Division of Hematology and Medical Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY

2. Department of Medicine, Columbia University Irving Medical Center, New York, NY

3. Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY

4. Department of Radiology, Columbia University Irving Medical Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.21.00550

Reference25 articles.

1. Kaposi sarcoma

2. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

3. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.

4. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.

5. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory effects of CDK4/6 inhibitors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07